Gedeon Richter’s Ryeqo (relugolix, estradiol, and norethindrone acetate) Receives NICE Recommendation for the Treatment of Women with Uterine Fibroids


NICE has issued final draft guidance recommending Ryeqo (40mg relugolix/1mg estradiol/0.5mg norethisterone acetate) for routine use in the NHS as a treatment option for heavy menstrual bleeding associated with UF
The P-III (LIBERTY) program consists of 2 P-III studies evaluating Ryeqo vs PBO in adult women with UF. The results showed that ≥71% vs 19% of women treated with Ryeqo responded to treatment, improved the symptoms i.e heavy menstrual bleeding & pain, and showed a well-tolerated safety profile
In the US, Relugolix and two hormonal therapies have been approved as Myfembree while Relugolix (GnRH antagonist) is also available as Orgovyx for prostate cancer

Ref: Pharmaphorum | Image: Gedeon Richter

Category: News